Both oral administration in drinking water and intraperitoneal injection produced significant pressure increases, though direct gastric application showed effects within minutes
Potential neuroprotective effects Early studies suggest a role in supporting nerve healing and cognitive health
This helps in illness prevention, muscle recovery, and healthier skin, nails, and hair
Mizuguchi M,Obita T,Nabeshima Y,Koizumi K,Toyooka N

coadministration of weight-based RBV is recommended if testing for Y93H is positive.[12] Additionally, the American Association for the Study of Liver Diseases recommends 12 weeks of SOF/VEL plus RBV, regardless of viral resistance testing, for prior pegIFN/RBV treatment-experienced patients with compensated cirrhosis, in part based on a modest increase in SVR12 rate observed with RBV coadministration in patients with cirrhosis and prior IFN-based treatment experience.[15] The European Association for the Study of the Liver recommends that patients with compensated cirrhosis and/or prior treatment experience who test positive for Y93H in nonstructural protein 5A (NS5A) should also have weight-based RBV coadministered with SOF/VEL.[13] Most recently the American Association for the Study of Liver Diseases recommended 12 weeks of glecaprevir/pibrentasvir for treatment-naive patients with GT3 infection and compensated cirrhosis, without the need for viral resistance testing or RBV coadministration

The abstract (but not the complete study) for the SURMOUNT-OSA trial was just published in the New England Journal of Medicine